Many investors view the health sector as a safe haven when the stock market is turbulent. That's understandable. Demand for healthcare products and services is usually held very well, regardless of what is happening in the market or economy.
Some healthcare stocks outperform others. And you don't need a lot of money to invest in some of the best. Here are three simple medical stocks that can be purchased for $1,000 now.
Many stocks have been pulled back significantly in the first few months of 2025 amid concerns about the Trump administration's trade policy. But it's not Abbvie (NYSE: ABBV). Stocks of major drug makers are up about 20% per year.
Abbvie's product lineup is led by blockbuster drugs targeting autoimmune diseases, with Rinvoq and Skyrizi bringing particularly strong sales growth. The company's cancer drugs Imbruvica and Venclexta are also big winners. With Abbvie's acquisition of Allergan, it has become a top player in the aesthetic market along with top sellers such as Botox and Juvederm.
At the time of writing, you'll be able to win a share of Abbvie for around $212. This is an attractive price considering the company's growth outlook. According to the Financial Data and Infrastructure Provider LSEG, the ratio of Abbvie to revenue to growth (PEG) based on a five-year revenue growth forecast is a very low of 0.45.
To add icing to the cake, Abbvie offers a fantastic forward dividend yield of 3.09%. The company is also the dividend king with a track record of increasing dividends for the 53rd consecutive year.
Apex drugs (NASDAQ: VRTX) It had even greater benefits than Abbvie in 2025. Stocks have soared more than 20% so far while the entire market is sinking. Part of the appeal of Vertex is that it orders a virtual monopoly when treating the underlying causes of cystic fibrosis (CF).
However, the peak has also benefited from two important US Food and Drug Administration (FDA) approvals in recent months. The FDA gave a thumbs up to its latest CF drug, Alyftrek, on December 20, 2024. On January 30, 2025, Vertex's non-opioid drug Journavx was approved to treat acute pain.
I fully hope that both of these drugs will become huge growth drivers at the top. Alyftrek is photographed once a day and is more convenient than the current flagship CF therapy Trikafta. Also, the peak is the royalties of new drugs and you don't have to pay that much. Journavx has particularly great market opportunities due to the addictive quality and negative side effects associated with opioids.
The story continues
